Cargando…
Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)
INTRODUCTION: Cirrhotic patients with portal hypertension can suffer from variceal bleeding or refractory ascites and can benefit from a transjugular intrahepatic portosystemic shunt (TIPS). Post-TIPS hepatic encephalopathy (HE) is a common (20%–54%) and often severe complication. A prophylactic str...
Autores principales: | de Wit, K, Schaapman, J J, Nevens, F, Verbeek, J, Coenen, S, Cuperus, F J C, Kramer, M, Tjwa, E T T L, Mostafavi, N, Dijkgraaf, M G W, van Delden, O M, Beuers, U H W, Coenraad, M J, Takkenberg, R B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783616/ https://www.ncbi.nlm.nih.gov/pubmed/33372103 http://dx.doi.org/10.1136/bmjgast-2020-000531 |
Ejemplares similares
-
Lactulose/rifaximin: Lack of drug effect: case report
Publicado: (2021) -
The Role of Percutaneous Transjugular Portosystemic Shunts
por: Gordon, Roy L.
Publicado: (1992) -
Racial disparities in transjugular intrahepatic portosystemic shunt procedure outcomes
por: Helzberg, James H, et al.
Publicado: (2022) -
Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005) -
Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)